HOUSTON–(BUSINESS WIRE)–Pharm-Olam,
a global, midsized CRO offering full-service clinical development
solutions for oncology-hematology, infectious diseases and vaccines, and
rare diseases, is marking its 25th anniversary with several
announcements. These include an update to its rare disease service tier,
progress on its transition to the Medidata Cloud platform, and ongoing
global expansion. With record sales in 2018, these changes position
Pharm-Olam for continued growth into 2019.

To provide increased support to sponsors, Pharm-Olam is enhancing its
rare disease services and elevating it to their Center of Excellence
(COE) tier, thus joining oncology-hematology as well as infectious
disease and vaccines in this category. This service tier offers sponsors
dedicated staff, enhanced technology, optimized processes, and site and
vendor partners to meet the unique demands and challenges of each COE
target research area.

“We have completed over 100 rare disease clinical trials covering more
than 30 indications, which have led to multiple drug marketing
authorizations by the FDA, EMA, and other regulatory bodies worldwide,”
said Pavle
Vukojevic, chief medical officer at Pharm-Olam. “This area of
research continues to see increased industry investment and public
awareness, and we will continue to invest and support our sponsors where
they need us most.”

To further bolster its clinical trial execution, Pharm-Olam and Medidata
earlier announced
an expansion of their relationship with a unique partnership to
utilize the full power of Medidata’s Cloud. In total, Pharm-Olam will
deploy over 15 Medidata products, and its sponsors will benefit from
cross communication, data sharing between systems, and study-portfolio
level analytics, thus providing a comprehensive solution for deeper
study insights and evidence-based decision making.

Additionally, Pharm-Olam cites its increased global reach, covering 65
countries, as a key competitive advantage enabling the company to
deliver clinical trials around the world. In 2018, the company added
operations in Australia, South Korea, Malaysia, Philippines, and
Thailand and will further expand in 2019.

Finally, as part of its 25th anniversary celebration, Pharm-Olam
International, LLC is now Pharm-Olam, LLC to match its global services
and positioning. “As we celebrate our anniversary, we are proud that our
offerings uniquely position us to execute everything from local trials
through large, global clinical trials,” said David
L. Grange, chief executive officer at Pharm-Olam. “Providing
exceptional service for challenging clinical trials has been our
hallmark. We continue to invest in our organization and in our sponsors;
we can’t wait to see where the next 25 years will take us.”

About Pharm-Olam
Pharm-Olam is Helping Create a Healthier
World as a global, midsized CRO that offers flexible, innovative, and
highly personalized clinical solutions to pharmaceutical, biotechnology,
and life science companies. Our team is well-known for producing quality
results with reduced risk, costs, and timelines in challenging
international trials. Learn more about our full-service solutions, data
protection services, and expertise in oncology, infectious diseases and
vaccines, rare and orphan diseases, pediatrics, and general medicine at pharm-olam.com.

Contacts

Jane Byram
SCORR Marketing
(512) 626-2758
[email protected]